Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study

Toshihiko Imamura, Shotaro Iwamoto, Rie Kanai, Akira Shimada, Kiminori Terui, Yuko Osugi, Ryoji Kobayashi, Akio Tawa, Yoshiyuki Kosaka, Koji Kato, Hiroki Hori, Keizo Horibe, Megumi Oda, Souichi Adachi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The acute myeloid leukaemia (AML) 99 trial conducted previously in Japan for the treatment of de novo paediatric AML showed excellent results, with a 5-year overall survival (OS) and event-free survival (EFS) of 75·6% and 61·6%, respectively. To examine reproducibility of these results in another cohort, the outcome of 146 newly diagnosed AML paediatric patients prospectively registered in the Japan Association of Childhood Leukaemia Study (JACLS) from 2003 to 2006 was compared to that of 240 patients in the original AML 99 clinical trial. The 5-year EFS and OS achieved in the new cohort was 66·7 ± 4·0% and 77·7 ± 8·0% respectively, which were comparable to those obtained in the original AML 99 clinical trial, although less frequent core-binding factor (CBF) AML (29·5% vs. 37%) and an almost equal frequency of allogeneic haematopoietic stem cell transplantation (allo-HSCT) during first complete remission (16·5% vs. 19%) were observed. The 5-year EFS in patients with a normal karyotype (NK) (n = 35, 54·9 ± 15·1%) was inferior in the present cohort when compared to the original AML99 trial. This study confirmed the excellent outcome of the original AML99 protocol.

Original languageEnglish
Pages (from-to)204-210
Number of pages7
JournalBritish Journal of Haematology
Volume159
Issue number2
DOIs
Publication statusPublished - Oct 2012
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Japan
Leukemia
Pediatrics
Disease-Free Survival
Core Binding Factors
Clinical Trials
Survival
Hematopoietic Stem Cell Transplantation
Karyotype
Reproducibility of Results

Keywords

  • Allo-HSCT
  • AML 99
  • Core-binding factor leukaemia
  • Japan Association of Childhood Leukaemia Study
  • Paediatric acute myeloid leukaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study. / Imamura, Toshihiko; Iwamoto, Shotaro; Kanai, Rie; Shimada, Akira; Terui, Kiminori; Osugi, Yuko; Kobayashi, Ryoji; Tawa, Akio; Kosaka, Yoshiyuki; Kato, Koji; Hori, Hiroki; Horibe, Keizo; Oda, Megumi; Adachi, Souichi.

In: British Journal of Haematology, Vol. 159, No. 2, 10.2012, p. 204-210.

Research output: Contribution to journalArticle

Imamura, T, Iwamoto, S, Kanai, R, Shimada, A, Terui, K, Osugi, Y, Kobayashi, R, Tawa, A, Kosaka, Y, Kato, K, Hori, H, Horibe, K, Oda, M & Adachi, S 2012, 'Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study', British Journal of Haematology, vol. 159, no. 2, pp. 204-210. https://doi.org/10.1111/bjh.12030
Imamura, Toshihiko ; Iwamoto, Shotaro ; Kanai, Rie ; Shimada, Akira ; Terui, Kiminori ; Osugi, Yuko ; Kobayashi, Ryoji ; Tawa, Akio ; Kosaka, Yoshiyuki ; Kato, Koji ; Hori, Hiroki ; Horibe, Keizo ; Oda, Megumi ; Adachi, Souichi. / Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study. In: British Journal of Haematology. 2012 ; Vol. 159, No. 2. pp. 204-210.
@article{1ba2be9221cb4969b813c9a9bf062bf6,
title = "Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study",
abstract = "The acute myeloid leukaemia (AML) 99 trial conducted previously in Japan for the treatment of de novo paediatric AML showed excellent results, with a 5-year overall survival (OS) and event-free survival (EFS) of 75·6{\%} and 61·6{\%}, respectively. To examine reproducibility of these results in another cohort, the outcome of 146 newly diagnosed AML paediatric patients prospectively registered in the Japan Association of Childhood Leukaemia Study (JACLS) from 2003 to 2006 was compared to that of 240 patients in the original AML 99 clinical trial. The 5-year EFS and OS achieved in the new cohort was 66·7 ± 4·0{\%} and 77·7 ± 8·0{\%} respectively, which were comparable to those obtained in the original AML 99 clinical trial, although less frequent core-binding factor (CBF) AML (29·5{\%} vs. 37{\%}) and an almost equal frequency of allogeneic haematopoietic stem cell transplantation (allo-HSCT) during first complete remission (16·5{\%} vs. 19{\%}) were observed. The 5-year EFS in patients with a normal karyotype (NK) (n = 35, 54·9 ± 15·1{\%}) was inferior in the present cohort when compared to the original AML99 trial. This study confirmed the excellent outcome of the original AML99 protocol.",
keywords = "Allo-HSCT, AML 99, Core-binding factor leukaemia, Japan Association of Childhood Leukaemia Study, Paediatric acute myeloid leukaemia",
author = "Toshihiko Imamura and Shotaro Iwamoto and Rie Kanai and Akira Shimada and Kiminori Terui and Yuko Osugi and Ryoji Kobayashi and Akio Tawa and Yoshiyuki Kosaka and Koji Kato and Hiroki Hori and Keizo Horibe and Megumi Oda and Souichi Adachi",
year = "2012",
month = "10",
doi = "10.1111/bjh.12030",
language = "English",
volume = "159",
pages = "204--210",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study

AU - Imamura, Toshihiko

AU - Iwamoto, Shotaro

AU - Kanai, Rie

AU - Shimada, Akira

AU - Terui, Kiminori

AU - Osugi, Yuko

AU - Kobayashi, Ryoji

AU - Tawa, Akio

AU - Kosaka, Yoshiyuki

AU - Kato, Koji

AU - Hori, Hiroki

AU - Horibe, Keizo

AU - Oda, Megumi

AU - Adachi, Souichi

PY - 2012/10

Y1 - 2012/10

N2 - The acute myeloid leukaemia (AML) 99 trial conducted previously in Japan for the treatment of de novo paediatric AML showed excellent results, with a 5-year overall survival (OS) and event-free survival (EFS) of 75·6% and 61·6%, respectively. To examine reproducibility of these results in another cohort, the outcome of 146 newly diagnosed AML paediatric patients prospectively registered in the Japan Association of Childhood Leukaemia Study (JACLS) from 2003 to 2006 was compared to that of 240 patients in the original AML 99 clinical trial. The 5-year EFS and OS achieved in the new cohort was 66·7 ± 4·0% and 77·7 ± 8·0% respectively, which were comparable to those obtained in the original AML 99 clinical trial, although less frequent core-binding factor (CBF) AML (29·5% vs. 37%) and an almost equal frequency of allogeneic haematopoietic stem cell transplantation (allo-HSCT) during first complete remission (16·5% vs. 19%) were observed. The 5-year EFS in patients with a normal karyotype (NK) (n = 35, 54·9 ± 15·1%) was inferior in the present cohort when compared to the original AML99 trial. This study confirmed the excellent outcome of the original AML99 protocol.

AB - The acute myeloid leukaemia (AML) 99 trial conducted previously in Japan for the treatment of de novo paediatric AML showed excellent results, with a 5-year overall survival (OS) and event-free survival (EFS) of 75·6% and 61·6%, respectively. To examine reproducibility of these results in another cohort, the outcome of 146 newly diagnosed AML paediatric patients prospectively registered in the Japan Association of Childhood Leukaemia Study (JACLS) from 2003 to 2006 was compared to that of 240 patients in the original AML 99 clinical trial. The 5-year EFS and OS achieved in the new cohort was 66·7 ± 4·0% and 77·7 ± 8·0% respectively, which were comparable to those obtained in the original AML 99 clinical trial, although less frequent core-binding factor (CBF) AML (29·5% vs. 37%) and an almost equal frequency of allogeneic haematopoietic stem cell transplantation (allo-HSCT) during first complete remission (16·5% vs. 19%) were observed. The 5-year EFS in patients with a normal karyotype (NK) (n = 35, 54·9 ± 15·1%) was inferior in the present cohort when compared to the original AML99 trial. This study confirmed the excellent outcome of the original AML99 protocol.

KW - Allo-HSCT

KW - AML 99

KW - Core-binding factor leukaemia

KW - Japan Association of Childhood Leukaemia Study

KW - Paediatric acute myeloid leukaemia

UR - http://www.scopus.com/inward/record.url?scp=84866858062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866858062&partnerID=8YFLogxK

U2 - 10.1111/bjh.12030

DO - 10.1111/bjh.12030

M3 - Article

C2 - 22924344

AN - SCOPUS:84866858062

VL - 159

SP - 204

EP - 210

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -